LEO Pharma US’ Post

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #AtopicEczemaDay

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #WorldAtopicEczemaDay #AtopicDermatitis

Komal Nandure and I are excited to highlight our latest insights into the innovative advancements in psoriasis treatment!" Did you know that new treatments for psoriasis are changing the way we manage this challenging skin condition? Psoriasis affects millions of people worldwide, often leading to discomfort and a reduced quality of life. As a healthcare professional, staying updated on the latest treatment options is crucial to improving patient outcomes. In our latest clinical review, we explore the advancements in both topical and systemic treatments for psoriasis. From new topical formulations to cutting-edge biologics and JAK inhibitors, this article dives into the most recent innovations, their mechanisms, and their clinical benefits. #Psoriasis #Dermatology #Healthcare #ClinicalReview #InnovativeTreatments

#Psoriasis affects 125 million people worldwide. It’s more than a skin condition—it can impact every aspect of life, bringing both physical discomfort and emotional strain. 🤝 This #WorldPsoriasisDay, we’re stepping up to support those living with plaque psoriasis, which accounts for 80-90% of cases. 📍 At Scinai Immunotherapeutics Ltd., we are dedicated to transforming psoriasis care. Our drug development program focuses on a targeted therapy specifically for mild to moderate plaque psoriasis. Leveraging single-domain antibodies (sdAbs), including our anti-IL-17A/F sdAb, we are advancing a locally administered biologic that combines high potency and convenience with a safer profile than current treatments. 👉 Join us in raising awareness and supporting those affected by psoriasis. Together, we can make a difference for millions. 🌐 Visit Scinai.com to learn more #InnovativeResearch #Healthcare #Biotechnology #Dermatology #WorldPsoriasisDay24

📊 One of the most rewarding aspects of being involved in new drug discovery is the opportunity to learn, even when outcomes don’t align with initial expectations. Our latest publication highlights a two-part trial of BI 730357, a RORγt inhibitor, in plaque #psoriasis. Congrats to my co-authors Kim Papp, Ulrich Mrowietz, Mary Flack, Howard Sofen, Werner Kadus, Kristin Drda, Hui Gu, Harald Vangerow, and Julia Korell 👏 https://lnkd.in/ggZJUR9s In summary, the study demonstrated moderate efficacy at doses up to 200 mg, with 30% of patients achieving PASI 75 and 27.5% reaching clear/almost clear skin (sPGA) at 12 weeks. The treatment was well-tolerated, with drug-related adverse events in ≤18.5% of patients during the long-term extension. The journey of studying all possibilities advances our understanding—and every step brings us closer to improved care for patients!! #Dermatology #DrugDiscovery #PsoriasisResearch #PsoriasisTherapeutics

The latest #psoriasis slide decks are now available on the #IMIDForum! Explore new insights and data to enhance your practice with the top research in #dermatology: [LINK] This month’s Literature Highlights are now available on the Immune-Mediated Inflammatory Disease Forum! November’s single slide summary includes a study by Huang, et al., where they aimed to identify predictors and construct a predictive model for time to relapse following withdrawal from biologics. Find out more about this publication, and more about #psoriasis on the IMID Forum today. 🔗https://ow.ly/z06850UhCMV

Check out the NACE Webcast: Atopic Dermatitis: Evaluation and Targeted Management. Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that commonly presents in childhood. It is characterized primarily by scaly, pruritic, erythematous lesions located on flexural surfaces. The itch that accompanies AD has a significant impact on patients’ quality of life, with the most prominent impact being on sleep quality. Fortunately, a new understanding of its underlying pathophysiology has brought about a variety of effective treatment options for patients suffering from AD, from topical agents to biologics and oral Janus kinase (JAK) inhibitors. In this webcast, Mona Shahriari, MD, FAAD, will share her valuable insights on differential diagnosis, treatment goals, and individualizing treatment plans. Click here to start the course: https://bit.ly/3WdObsm #NACE #Dermatology #Webcast

Sharayu Kachare and I are excited to highlight our latest insights into the innovative advancements in psoriasis treatment!" Did you know that new treatments for psoriasis are changing the way we manage this challenging skin condition? Psoriasis affects millions of people worldwide, often leading to discomfort and a reduced quality of life. As a healthcare professional, staying updated on the latest treatment options is crucial to improving patient outcomes. In our latest clinical review, we explore the advancements in both topical and systemic treatments for psoriasis. From new topical formulations to cutting-edge biologics and JAK inhibitors, this article dives into the most recent innovations, their mechanisms, and their clinical benefits. #Psoriasis #Dermatology #Healthcare #ClinicalReview #InnovativeTreatments

In recognition of #MelanomaAwarenessMonth, AMLo Biosciences are sharing (to US-only audience) a patient case study demonstrating the clinical utility of their #AMBLor technology that accurately stratifies early-stage, low-risk melanomas. https://lnkd.in/eehgYpVY AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers